- Home
- SNSE vs MTNB Comparison
SNSE vs MTNB Comparison
Compare SNSE & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- MTNB
- Stock Information
- Founded
- SNSE 2005
- MTNB 2013
- Country
- SNSE United States
- MTNB United States
- Employees
- SNSE N/A
- MTNB N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- MTNB Health Care
- Exchange
- SNSE Nasdaq
- MTNB Nasdaq
- Market Cap
- SNSE 10.3M
- MTNB 10.8M
- IPO Year
- SNSE 2021
- MTNB N/A
- Fundamental
- Price
- SNSE $8.60
- MTNB $0.74
- Analyst Decision
- SNSE Strong Buy
- MTNB
- Analyst Count
- SNSE 5
- MTNB 0
- Target Price
- SNSE $72.50
- MTNB N/A
- AVG Volume (30 Days)
- SNSE 39.5K
- MTNB 23.3K
- Earning Date
- SNSE 11-14-2025
- MTNB 11-10-2025
- Dividend Yield
- SNSE N/A
- MTNB N/A
- EPS Growth
- SNSE N/A
- MTNB N/A
- EPS
- SNSE N/A
- MTNB N/A
- Revenue
- SNSE N/A
- MTNB N/A
- Revenue This Year
- SNSE N/A
- MTNB N/A
- Revenue Next Year
- SNSE N/A
- MTNB N/A
- P/E Ratio
- SNSE N/A
- MTNB N/A
- Revenue Growth
- SNSE N/A
- MTNB N/A
- 52 Week Low
- SNSE $5.00
- MTNB $0.47
- 52 Week High
- SNSE $18.35
- MTNB $3.09
- Technical
- Relative Strength Index (RSI)
- SNSE 44.73
- MTNB 25.92
- Support Level
- SNSE $8.37
- MTNB $0.70
- Resistance Level
- SNSE $9.42
- MTNB $1.30
- Average True Range (ATR)
- SNSE 1.08
- MTNB 0.11
- MACD
- SNSE -0.02
- MTNB -0.03
- Stochastic Oscillator
- SNSE 33.45
- MTNB 9.92
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.